TG Therapeutics Inc. [TGTX] Revenue clocked in at $2.80 million, up 20.46% YTD: What’s Next?

TG Therapeutics Inc. [NASDAQ: TGTX] loss -4.49% or -0.67 points to close at $14.25 with a heavy trading volume of 3794618 shares. The company report on March 3, 2023 that TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting.

Poster Presentation Title: Ublituximab, a Novel, Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Enhanced Antibody-Dependent Cellular Cytotoxicity (ADCC) Relative to Other Anti-CD20 mAbs.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.


It opened the trading session at $14.54, the shares rose to $14.885 and dropped to $14.0663, the range by which the price of stock traded the whole day. The daily chart for TGTX points out that the company has recorded 116.24% gains over the past six months. However, it is still -309.48% lower than its most recent low trading price.

If we look at the average trading volume of 5.84M shares, TGTX reached to a volume of 3794618 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about TG Therapeutics Inc. [TGTX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TGTX shares is $19.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TGTX stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

BofA Securities have made an estimate for TG Therapeutics Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on May 20, 2022. While these analysts kept the previous recommendation, B. Riley Securities dropped their target price from $49 to $35. The new note on the price target was released on February 23, 2022, representing the official price target for TG Therapeutics Inc. stock. Previously, the target price had yet another drop from $33 to $26, while Goldman kept a Sell rating on TGTX stock.

The Average True Range (ATR) for TG Therapeutics Inc. is set at 1.09, with the Price to Sales ratio for TGTX stock in the period of the last 12 months amounting to 738.35. The Price to Book ratio for the last quarter was 33.14, with the Price to Cash per share for the same quarter was set at 1.11.

Trading performance analysis for TGTX stock

TG Therapeutics Inc. [TGTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.65. With this latest performance, TGTX shares dropped by -12.42% in over the last four-week period, additionally plugging by 116.24% over the last 6 months – not to mention a rise of 46.91% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TGTX stock in for the last two-week period is set at 40.85, with the RSI for the last a single of trading hit 35.74, and the three-weeks RSI is set at 45.21 for TG Therapeutics Inc. [TGTX]. The present Moving Average for the last 50 days of trading for this stock 15.66, while it was recorded at 14.64 for the last single week of trading, and 8.96 for the last 200 days.

TG Therapeutics Inc. [TGTX]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and TG Therapeutics Inc. [TGTX] shares currently have an operating margin of -6924.20 and a Gross Margin at +71.99. TG Therapeutics Inc.’s Net Margin is presently recorded at -7121.54.

Return on Total Capital for TGTX is now -84.24, given the latest momentum, and Return on Invested Capital for the company is -87.40. Return on Equity for this stock declined to -134.13, with Return on Assets sitting at -69.20. When it comes to the capital structure of this company, TG Therapeutics Inc. [TGTX] has a Total Debt to Total Equity ratio set at 141.77. Additionally, TGTX Total Debt to Total Capital is recorded at 58.64, with Total Debt to Total Assets ending up at 42.91. Long-Term Debt to Equity for the company is recorded at 139.07, with the Long-Term Debt to Total Capital now at 57.52.

Reflecting on the efficiency of the workforce at the company, TG Therapeutics Inc. [TGTX] managed to generate an average of -$877,588 per employee. Receivables Turnover for the company is 4.01 with a Total Asset Turnover recorded at a value of 0.01.TG Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.20 and a Current Ratio set at 3.20.

An analysis of insider ownership at TG Therapeutics Inc. [TGTX]

There are presently around $1,332 million, or 69.70% of TGTX stock, in the hands of institutional investors. The top three institutional holders of TGTX stocks are: VANGUARD GROUP INC with ownership of 15,502,764, which is approximately 5.129% of the company’s market cap and around 1.10% of the total institutional ownership; STATE STREET CORP, holding 10,415,161 shares of the stock with an approximate value of $148.42 million in TGTX stocks shares; and BLACKROCK INC., currently with $130.16 million in TGTX stock with ownership of nearly 1.095% of the company’s market capitalization.

Positions in TG Therapeutics Inc. stocks held by institutional investors increased at the end of Tuesday and at the time of the Tuesday reporting period, where 106 institutional holders increased their position in TG Therapeutics Inc. [NASDAQ:TGTX] by around 13,684,685 shares. Additionally, 86 investors decreased positions by around 20,352,794 shares, while 34 investors held positions by with 59,440,153 shares. The mentioned changes placed institutional holdings at 93,477,632 shares, according to the latest SEC report filing. TGTX stock had 42 new institutional investments in for a total of 2,119,687 shares, while 28 institutional investors sold positions of 5,960,753 shares during the same period.


Please enter your comment!
Please enter your name here